Report Description
The leading business intelligence provider, has released its latest research “Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market”, which provides insights into sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders R&D pipeline. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatments is also presented.
Scope
The report covers:
Data and analysis on the sleep disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
Annualized market data for the sleep disorders therapeutics market from 2002 to 2010, with forecasts to 2017.
Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
Key drivers and restraints that have had a significant impact on the market.
The competitive landscape of the global sleep disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Sanofi-aventis, King pharmaceuticals, questcor pharmaceuticals, Novartis, GlaxoSmithKline, plc, Pfizer and Boehringer Ingelheim
Key M&A activities and Licensing Agreements that took place in 2008 and 2010 in the sleep disorders therapeutics market.
Reasons to Buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to:
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
For more information, please visit :
http://www.aarkstore.com/reports/Sleep-Disorders-Market-to-2017-Generic-Substitution-Coupled-With-a-Weak-Pipeline-Will-Negatively-Impact-the-Market-116641.html
Contact us at :
Aarkstore Enterprise
Tel: +919272852585
Email: [email protected]
Website: www.aarkstore.com
Blog: http://blogs.aarkstore.com/
